Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 26;57(9):e00344-19.
doi: 10.1128/JCM.00344-19. Print 2019 Sep.

Analysis of Infection Loads in Mycoplasma genitalium Clinical Specimens by Use of a Commercial Diagnostic Test

Affiliations

Analysis of Infection Loads in Mycoplasma genitalium Clinical Specimens by Use of a Commercial Diagnostic Test

Gerald L Murray et al. J Clin Microbiol. .

Abstract

Mycoplasma genitalium is a common sexually transmitted infection with a propensity to acquire resistance to commonly used antimicrobial therapies. Bacterial load has been linked to patient symptoms and the success of treatment. In this study, we demonstrate methodology to estimate load from routine diagnostic assays using the ResistancePlus MG test (SpeeDx Pty Ltd., Australia). The method gave comparable quantitation to an M. genitalium-specific 16S rRNA quantitative PCR (qPCR; Spearman r = 0.94) for the samples analyzed (n = 499, including urine and swab types as detailed below) and was, therefore, employed to analyze typical load levels for samples in a diagnostic laboratory (total of 1,012 tests). When stratified by sample type, female urine (median, 826 genomes/ml) had the lowest load. This was significantly lower than median loads for all other sample types (male urine [6.91 × 103 genomes/ml], anal swabs [5.50 × 103], cervical swabs [8.15 × 103], endocervical swabs [3.97 × 103], and vaginal swabs [6.95 × 103]) (P < 0.0001). There were no significant differences in load estimates between the other sample types. Reproducibility of load estimates conducted on the same samples was high (r > 0.85). In conclusion, this methodology to provide load estimates for M. genitalium can be easily integrated into routine diagnostic laboratory workflow. Given the association between organism load, symptoms, and treatment success, load assessment has future diagnostic potential.

Keywords: Mycoplasma genitalium; diagnostic test; infection load; sample type; urine.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Overview of sample collection, data extraction, and analysis. (A) For 531 diagnostic tests, data extraction was performed from the routine diagnostic ResistancePlus MG assay. A 16S rRNA qPCR was performed on a subset of 499 samples for a comparison of load estimation methods. (B) Data were extracted for routine diagnostic ResistancePlus MG assay for an additional 481 samples and combined with the results for the 531 samples (from above), making a total of 1,012 samples.
FIG 2
FIG 2
Comparison of load estimation by 16S rRNA qPCR and ResistancePlus MG assay. Sample loads (genome equivalents per 5-μl sample extract) were graphed in a scatter plot with linear regression.
FIG 3
FIG 3
Diagnostic specimen sample loads stratified by sample type. Sample loads estimated from the ResistancePlus MG assay (expressed as genome equivalents per swab or per 1 ml for urine) were log10 transformed and plotted. Analysis of the range and distribution of loads is presented in tabular form. Whiskers represent the 10th/90th percentiles, and outliers are indicated. Samples types not represented in the figure include urethral swabs (n = 7), rectal swab (n = 1), and urine samples where sex was indicated as “other” (n = 2). Only the median for female urine samples was significantly different to other sample types (P < 0.0001).
FIG 4
FIG 4
Analysis of the reproducibility of load estimates. Sample load estimates for the primary test (log transformed, n = 39 samples) were separately compared with two repeat analysis tests by scatter plot with linear regression.

Similar articles

Cited by

References

    1. Lis R, Rowhani-Rahbar A, Manhart LE. 2015. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 61:418–426. doi:10.1093/cid/civ312. - DOI - PubMed
    1. Read TRH, Fairley CK, Murray GL, Jensen JS, Danielewski J, Worthington K, Doyle M, Mokany E, Tan L, Chow EPF, Garland SM, Bradshaw CS. 2019. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis 68:554–560. doi:10.1093/cid/ciy477. - DOI - PMC - PubMed
    1. Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, Fairley CK, Tabrizi SN. 2017. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 23:809–812. doi:10.3201/eid2305.161745. - DOI - PMC - PubMed
    1. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, Vodstrcil LA, Jensen JS, Hocking JS, Garland SM, Bradshaw CS. 2015. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis 60:1228–1236. doi:10.1093/cid/ciu1162. - DOI - PubMed
    1. Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Twin J, Chen MY, Taylor N, Donovan B, Kaldor JM, McNamee K, Urban E, Walker S, Currie M, Birden H, Bowden FJ, Gunn J, Pirotta M, Gurrin L, Harindra V, Garland SM, Hocking JS. 2013. Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women. Clin Infect Dis 56:1094–1100. doi:10.1093/cid/cis1210. - DOI - PubMed

Publication types

LinkOut - more resources